Zynerba Pharmaceuticals (ZYNE): Presentation from conference http://ir....

Send PM Follow Ignore

Followers	185
Posts	2462
Boards Moderated	0
Alias Born	02/10/2017

Fress

Re: iluvtofu post# 1136

Wednesday, 03/20/2019 9:05:00 AM

Wednesday, March 20, 2019 9:05:00 AM

Presentation from conference
http://ir.zynerba.com/static-files/1a4c0483-3e61-43d7-a160-ddfc45f68b64

• Clean balance sheet • No debt, 21.1M shares outstanding (as of 3/7/19) • Strong cash and cash equivalent position • $59.8 million (as of 12/31/18) • Additional $18.1M in net cash proceeds from shares sold under ATM from 1/29/19 through 3/6/19 • Expected to be sufficient to fund operations and capital requirements beyond the planned NDA submission and potential approval in FXS and into the first quarter of 2021

Deep Pipeline

In a recently released analyst research report, H.C. Wainwright‘s Managing Director of Equity Research and Senior Healthcare Analyst, Oren G. Livnat, CFA, just reiterated his buy rating on shares of Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) with a higher price target. Oren G. Livnat, CFA’s price target of $23.00 USD per share… Thats 330% upside from a 5 star Analyst.

http://www.zynerba.com